PE20241236A1 - Composiciones y metodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinacion de thc y melatonina - Google Patents

Composiciones y metodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinacion de thc y melatonina

Info

Publication number
PE20241236A1
PE20241236A1 PE2024000480A PE2024000480A PE20241236A1 PE 20241236 A1 PE20241236 A1 PE 20241236A1 PE 2024000480 A PE2024000480 A PE 2024000480A PE 2024000480 A PE2024000480 A PE 2024000480A PE 20241236 A1 PE20241236 A1 PE 20241236A1
Authority
PE
Peru
Prior art keywords
compositions
thc
compound
melatonin
methods
Prior art date
Application number
PE2024000480A
Other languages
English (en)
Spanish (es)
Inventor
Ramachandra Mukunda
Jagadeesh S Rao
Original Assignee
Igc Pharma Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igc Pharma Ip Llc filed Critical Igc Pharma Ip Llc
Publication of PE20241236A1 publication Critical patent/PE20241236A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2024000480A 2021-09-17 2022-09-16 Composiciones y metodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinacion de thc y melatonina PE20241236A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163245799P 2021-09-17 2021-09-17
PCT/US2022/076579 WO2023044433A1 (en) 2021-09-17 2022-09-16 Compositions and methods for treating patients with dementia due to alzheimer's disease with a combination of thc and melatonin

Publications (1)

Publication Number Publication Date
PE20241236A1 true PE20241236A1 (es) 2024-06-19

Family

ID=83688895

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024000480A PE20241236A1 (es) 2021-09-17 2022-09-16 Composiciones y metodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinacion de thc y melatonina

Country Status (8)

Country Link
US (1) US20250275935A1 (enExample)
EP (1) EP4401717A1 (enExample)
JP (1) JP2024535871A (enExample)
CA (1) CA3232209A1 (enExample)
CL (1) CL2024000782A1 (enExample)
CO (1) CO2024004628A2 (enExample)
PE (1) PE20241236A1 (enExample)
WO (1) WO2023044433A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010284A (es) 2018-03-30 2021-02-18 India Globalization Capital Inc Método y composición para el tratamiento de los trastornos del snc.
CN121040357A (zh) * 2024-06-04 2025-12-02 河北农业大学 一种增加黄水仙生物碱加兰他敏的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR44305E (fr) 1933-12-09 1934-12-24 Meaf Mach En Apparaten Fab Nv Circuits de voie à rails sans potentiel ou portés au même potentiel
US11065225B1 (en) 2015-07-30 2021-07-20 University Of South Florida Ultra-low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's disease
US10525093B2 (en) * 2016-11-14 2020-01-07 Farm To Farma, Inc. Cannabinoid formulations and method of making the same
US20200246404A1 (en) * 2017-02-15 2020-08-06 Molecular Infusions, Llc Formulations
WO2018152334A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
WO2019036243A1 (en) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
MX2020010284A (es) 2018-03-30 2021-02-18 India Globalization Capital Inc Método y composición para el tratamiento de los trastornos del snc.
EP4025199A4 (en) * 2019-07-12 2023-08-02 University of South Florida Compositions and methods for treating alzheimers disease

Also Published As

Publication number Publication date
CO2024004628A2 (es) 2024-05-10
CA3232209A1 (en) 2023-03-23
EP4401717A1 (en) 2024-07-24
JP2024535871A (ja) 2024-10-02
US20250275935A1 (en) 2025-09-04
CL2024000782A1 (es) 2024-09-23
WO2023044433A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
Farokhnia et al. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study
CL2021003452A1 (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades.
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
MX2021015499A (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades.
MX2017011280A (es) Terapia neuro-afectiva regional topica con cannabinoides.
CO2024004628A2 (es) Composiciones y métodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinación de thc y melatonina
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
CA2956919C (en) Method for treating radiotherapy- and chemotherapy-associated cognitive or emotional impairment with cannabinoids
MX2025012013A (es) Protac de irak4
CR20220250A (es) Métodos para el tratamiento de trastornos depresivos
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição
CL2023001580A1 (es) Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección
MX2019002047A (es) Metodos y composiciones para tratar infecciones fungicas cutaneas.
DOP2024000203A (es) Composición que comprende n-acetilcisteína, vitamina d y preferentemente glutatión, usos de la misma, y composiciones farmacéuticas y nutracéuticas de los mismos
EP2424536A4 (en) NEW PHOTOSENSIBILIZER FORMULATIONS FOR ORAL ADMINISTRATION
MX2021013807A (es) Tratamiento de enfermedad ocular.
GT200600274A (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado y su uso como agentes farmacétuicos
Kumar Neurotherapeutic Potential of Withania somnifera: Insights From Ayurvedic Medicine
CO2023009313A2 (es) Derivados de 2h-indazol como inhibidores de irak4 y su uso en el tratamiento de enfermedades
MX2022002451A (es) Metodos para el tratamiento de la enfermedad cln2 en sujetos pediatricos.
CN105451749A (zh) 吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用
Cosentino et al. New approach for treatment of radiotherapy-induced peripheral neuropathy: a pilot observational study
RU2566201C1 (ru) Способ лечения витилиго
Panteleeva et al. Clinical experience and perspectives of using asenapine in stopping acute endogenous psychosis